‘Gonzalez Diet’ to Be Tested in Pancreatic Cancer
NEW YORK-An innovative clinical trial to be conducted at Columbia University is now recruiting patients with advanced pancreatic cancer. The patients will test the effectiveness of the “Gonzalez regimen,” which combines a strict diet of fresh fruits, vegetable juices, dietary supplements, and pancreatic enzyme extracts with a “detoxification” program. John Chabot, MD, a surgical oncologist at Columbia, is the principal investigator.
NEW YORKAn innovative clinical trial to be conducted at Columbia University is now recruiting patients with advanced pancreatic cancer. The patients will test the effectiveness of the Gonzalez regimen, which combines a strict diet of fresh fruits, vegetable juices, dietary supplements, and pancreatic enzyme extracts with a detoxification program. John Chabot, MD, a surgical oncologist at Columbia, is the principal investigator.
The researchers are seeking 72 to 90 patients with advanced pancreatic cancer for the phase III randomized study, which is being sponsored by the NCIs newly established Office of Cancer Complementary and Alternative Medicine. Half the patients will receive standard therapy with gemcitabine (Gemzar), while the other half will take the Gonzalez regimen.
Pilot Study Promising
The trial, which was given a 5-year, $250,000 grant, is applying scientific methods to assess the efficacy of this alternative treatment. The NCI agreed to test the regimen after Nicholas Gonzalez, MD, a New York endocrinologist, conducted a pilot study of his protocol from 1993 to 1996. The results, reported earlier this year in Nutrition and Cancer, showed that 9 of 11 pancreatic patients survived for 1 year, five survived for 2 years, and four survived for 3 years.
For information about patient entry to the trial, contact Michelle Gabay, RN (212-305-9468) at Columbia Presbyterian Cancer Center.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
FDA Updates Indication for Pembrolizumab in HER2+ Gastric/GEJ Adenocarcinoma
November 9th 2023Only patients with PD-L1–positive tumors may receive treatment with pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma following the FDA’s amendment.
Domvanalimab Plus Zimberelimab Improve Efficacy in Gastrointestinal Cancers
November 7th 2023Results from arm A1 of the phase 2 EDGE-Gastric study indicate that patients with gastric, gastroesophageal junction, and esophageal adenocarcinoma experienced improved responses after receiving domvanalimab/zimberelimab.
